Home  >  Chronicle Specials
you can get e-magazine links on WhatsApp.Click here
Pioma_Lactic
Chronicle Specials
+ Font Resize -

CPhI & P-MEC India scripts new pharma growth story

A D Pradeep Kumar
Thursday, November 25, 2021, 08:00 Hrs  [IST]

The Covid-19 pandemic has brought unprecedented challenges to the global pharma market. While growth in developed markets has slackened during this period, emerging markets are gaining salience with Indian pharma spearheading the growth momentum. India plays an overarching role in global pharma scene being the largest generic drugs provider.

Even as the impact of the debilitating pandemic is abating, the Indian pharma is rapidly expanding its footprint in the global pharma landscape. Industry experts are upbeat on the prospects of Indian pharma on the global stage.

Indian pharma performance in the international market was exceptional. During the pandemic period (FY-21), India’s pharma exports crossed $24.4  billion which is the highest growth of 18.4 per cent ever recorded over nine years period in the country. It is estimated that   the country exports $ 40,000 worth of pharmaceuticals every minute.

At the same time, the leading Indian listed pharmaceutical companies also registered an impressive performance during the financial year ended March 2021. The pharma industry in India is valued at $41.7 billion in 2020-2021.

Ravi Uday Bhaskar, director general of Pharmaceuticals Export Promotion Council of India (Pharmexcil) said that during the pandemic period, the main reason for India’s rapid export is due to the fact many developed countries could not cope with the high demand of products used in Covid management.  India fortunately could gear up and meet the most of the requirements. While the generic medicine market in 2020 calendar year grew just three per cent, India’s exports of generics grew to a whopping 19.53 per cent during FY-21.

CPhI & P-MEC India expo
In this context the 14th edition of South Asia’s biggest Pharma event, CPhI & P-MEC India expo being held from November 24 to 26, 2021 at the India Expo Centre, Greater Noida, Delhi – NCR is all the more relevant because it will further bolster the prospects of the Indian Pharma.

A new CPhI analysis points to sustained pharma growth in India, with an improving outlook for finished dosage, API and biologics. With a 15 per cent growth rate annually, the India pharma market with strong local manufacturing capabilities and an international export profile, is poised to capture new market trends, innovate and adapt to script a new growth story, aver experts.

Originating from CPhI Worldwide – CPhI India has become South Asia’s leading pharma meeting place covering every step of the supply chain from drug discovery to finished dosage, encompassing CROs, CMOs, and manufacturers of API, generics, excipients and drug formulation, fine chemicals, biosimilars, finished formulations, lab chemicals and biotechnology.

P-MEC, on the other hand, includes manufacturers of pharma machinery and equipment, analytical equipment, automation & robotics, packaging equipment & supplies, plant / facility equipment, automation & controls, processing equipment, RFID, tableting / capsule fillers, cleanroom equipment, filling equipment and laboratory products.

An all-inclusive platform
With the impressive response received from the industry, over 534 exhibitors from 16 countries are expected at the event. CPhI & P-MEC continues to provide an all-inclusive platform to scores of domestic and international buyers and professionals from across the pharmaceuticals and manufacturing space along with national and state regulatory boards, and policymakers to congregate and conduct business, arrive at solution-driven innovations to counteract economic uncertainties and domestic trade in India.

With a focus on building new business partnerships and announcements, the three-day expo promises to deliver and discuss new trends in the industry to grow the economy.  Keeping up with their annual promise, the event will host an exciting line-up of conferences expected to enlighten the guests by addressing the challenges and focusing on future opportunities of the pharmaceutical industry in India while adapting and thriving in this ever-changing industry.

The hybrid model ‘CPhI P-MEC India Virtual Conference’ has an exciting line-up of discussion points that will be covered over the four days, touching upon key topics like; Drug Development and Delivery, ­ Medical devices, ­ SCM (Logistics, Exports, Outsourcing), Machinery & Manufacturing, ­ API & Next-Gen Labs,­ Regulatory Updates, ­ Regulatory Updates, Biosimilars, mAbs,­ Pricing & Market Access, Packaging & Labelling, Serialisation, Track & Trace,­ Digitalization - AI, IoT, Blockchain, Big Data in Pharma.

Power -packed sessions
With an exciting line-up of conferences, CPhI & P-MEC India Expo will host a series of sessions and workshops, presented and led by high-profile speakers and industry stalwarts, and ample support and representation from the Government covering content from all aspects of the pharmaceutical industry. A keynote on ‘Recent initiatives by the authorities for the pharmaceutical and healthcare industry at the inauguration ceremony on the first day will be followed by a first-panel discussion ‘Building Self Reliance at the core of the Pharmaceutical Industry with reduced import dependence for API’ will focus on The Covid-19 pandemic that has disrupted the global supply chains and laid bare vulnerabilities across the world in critical industries such as pharmaceuticals and food. This will be followed by the second and third-panel discussion.

The expo is a part of the offerings under the umbrella of the popular India Pharma Week which ekes out solutions to challenges, and meets the business requirements of the pharma professional. This year too, apart from the expo, the IPW will have powerful sessions under their banner.

On the first day, the offerings include The Pharma Connect Conference which brings all key stakeholders in the pharmaceutical industry on a single platform to discuss, deliberate, and shares their thoughts on achieving the next phase of growth in pharma.

The CEO Roundtable which is a closed-door strategic gathering of CEOs of leading pharma and biopharma companies who deep dive into thought-provoking discussions on pharma developments in India, and concludes with the India Pharma Awards, one of the most transparent & process driven awards which are conducted professionally as well as methodically to draw out the best in the industry.

This will be followed by the Women in Pharma Roundtable on the second day, which is an initiative aimed at acknowledging and celebrating the significant and continued contribution of women to the pharmaceutical industry in a closed-door roundtable discussion.

Positive response from global delegates
Commenting on this year’s CPhI & P-MEC India Expo, Yogesh Mudras, Managing Director, Informa Markets in India, the organizer of the event, said, “The CPhI & P-MEC India Expo is an inherent part of our magnum opus, India Pharma Week (IPW), an array of marquee events celebrating the pharma industry. Always staying sensitive and true to trends, this year the theme for the IPW is really to Reconnect and Rebuild, to achieve the next phase of growth for the Indian pharma domain. With a 15 per cent growth rate annually, the India pharmaceutical market is a well-established sector, strong local manufacturing capabilities, with an international export profile, and therefore, it is important to capture new market trends, innovate, adapt and seek newer opportunities to reach goals. We are extremely thrilled to set ourselves back on track with this year’s expo, and while we are still fighting the global pandemic, we are delighted to see such a positive response from our international delegates.”

According to industry experts, the CPhi/P- MEC is an event they look forward to year on year, as it boosts business, both domestically and internationally.  India being the third-largest medicine market in the Asia Pacific, the outlook has always been positive.

Significant jump in global reputation
The India-specific findings of the CPhI Annual Report survey conducted among 350 executives, point to a significant jump in the country’s global reputation with India widely perceived to be benefiting from post pandemic macro-economic and supply chain changes.

India’s[DA1] [DA2]  single biggest metric improvement in the CPhI data was in the perceived quality of ‘finished dose manufacturing’, where the country surged 13 per cent in year, adding to the four per cent rise in saw in 2020, while it also jointly topped the prestigious ‘growth potential’ category with the United States for the first time.

India also saw its reputation for API manufacturing improve by seven per cent year-on-year. Emphasising this shift in perspectives, in 2021 there has been a five-fold increase in private equity investments totalling $1.5 billion into API companies across the country.

In another boon to Indian manufacturing, the country showed the largest gains in terms of ‘growth potential for biologics manufacturing’ of any country – including traditional biologics powerhouses France, the USA, Singapore, and the UK –helped by the Serum Institute of India’s well documented supply of Covid vaccines.

Exponential growth in pharma, healthcare sectors
According to Sagacious IP report, India is amongst the top 10 countries in pharma and healthcare sector with exponential growth recorded in the last five years.

The research stated that the patents with Indian publication as well as Indian priority have grown from 2,548 in 2015 to 7,399 in 2020. Such numbers are indicative of increased patent filing activity by Indian companies and MNCs with research centres based in India.

The pharma and healthcare sector have also seen a massive growth in global patent filings in the last five years - from over 24,000in 2015 to over 150,000 in 2020.

Even as globally the filing of pharmaceutical-related patent applications reported a modest growth over a period of time, India has been bullish in terms of filing applications in the pharmaceutical sector, according to World Intellectual Property Indicators 2021, a report released by the World Intellectual Property Organisation (WIPO).

Globally pharmaceuticals-related patents only grew by a modest 2.7 per cent over a period of 2009-2019 from 73,865 published applications in 2009 to 96,737 published applications in 2019. However, almost 17.8 per cent of the total published applications from applicants residing in India were into pharmaceuticals from 2017.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |